Aphena Pharma Solutions Inc. has announced the expansion of its blister packaging capacity with the purchase of a PharmaWorks TF2 blister packaging line with in-line cartoning capabilities, supplementing its recent vault enlargement to handle emerging requirements for DEA-controlled products.
Baxter International Inc. (NYSE:BAX), a global innovator in renal care, announced today that the first patients have been enrolled in a U.S. clinical trial for the company’s on-demand peritoneal dialysis (PD) solution generation system.
Adaptive Biotechnologies, an immune-driven medicine company, today announced that it will enter into a worldwide collaboration and license agreement with Genentech, a member of the Roche Group, to develop, manufacture and commercialize novel neoantigen directed T-cell therapies for the treatment of a broad range of cancers.
Harbour BioMed announced the appointment of Atul Deshpande, Ph.D. MBA, as Chief Strategy Officer and Head of U.S. Operations. Dr. Deshpande joins Harbour BioMed from Sanofi, where he served as Global Operations Lead of Sanofi Genzyme’s Dupixent® (dupilumab) franchise.
Alexion Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved ULTOMIRIS™ (ravulizumab-cwvz), the first and only long-acting C5 complement inhibitor administered every eight weeks, for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH), a debilitating ultra-rare blood disorder characterized by complement-mediated destruction of the red blood cells (hemolysis).
Biopharmaceutical company Alvotech announced today that Japan-based Fuji Pharma has acquired a 4.2% stake in the business for approximately US$50 million.
East River BioSolutions announced the release of NativeCoat™ ECM – a novel line of 2D in vitro cell culture coatings comprised of native tissue-derived extracellular matrix (ECM) that enables scientists to study cells in their tissue-specific microenvironments, leading to more physiologically relevant testing and thus more accurate and actionable scientific results.
Sobi, an international biopharmaceutical company dedicated to rare diseases, and Novimmune SA, a Swiss biotech company, today announced that the U.S. Food and Drug Administration (FDA) has approved Gamifant® (emapalumab-lzsg)..
Cycle Pharmaceuticals (Cycle) is pleased to announce that it has obtained the required stability data to extend the shelf life of NITYR™ (nitisinone) tablets from 24 to 36 months at room temperature.
Nexus Pharmaceuticals announced today the immediate availability in the United States for Arsenic Trioxide Injection. Nexus Pharmaceuticals’ Arsenic Trioxide Injection is available as 10mg per 10mL vial for injection.